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Selective Estrogen Receptor
Modulators: Cannabinoid Receptor
Inverse Agonists with Differential
CB1 and CB2 Selectivity
Lirit N. Franks, Benjamin M. Ford and Paul L. Prather*
Department of Pharmacology and Toxicology, University of Arkansas for Medical Sciences, Little Rock, AR, USA
Selective estrogen receptor modulators (SERMs) are used to treat estrogen receptor
(ER)-positive breast cancer and osteoporosis. Interestingly, tamoxifen and newer classes
of SERMs also exhibit cytotoxic effects in cancers devoid of ERs, indicating a non-
estrogenic mechanism of action. Indicative of a potential ER-independent target, reports
demonstrate that tamoxifen binds to cannabinoid receptors (CBRs) with affinity in
the low µM range and acts as an inverse agonist. To identify cannabinoids with
improved pharmacological properties relative to tamoxifen, and further investigate
the use of different SERM scaffolds for future cannabinoid drug development, this
study characterized the affinity and activity of SERMs in newer structural classes
at CBRs. Fourteen SERMs from five structurally distinct classes were screened for
binding to human CBRs. Compounds from four of five SERM classes examined
bound to CBRs. Subsequent studies fully characterized CBR affinity and activity of
one compound from each class. Ospemifine (a triphenylethylene) selectively bound to
CB1Rs, while bazedoxifine (an indole) bound to CB2Rs with highest affinity. Nafoxidine
(a tetrahydronaphthalene) and raloxifene (RAL; a benzothiaphene) bound to CB1 and
CB2Rs non-selectively. All four compounds acted as inverse agonists at CB1 and
CB2Rs, reducing basal G-protein activity with IC50 values in the nM to low µM range.
Ospemifine, bazedoxifene and RAL also acted as inverse agonists to elevate basal
intracellular cAMP levels in intact CHO-hCB2 cells. The four SERMs examined also
acted as CB1 and CB2R antagonists in the cAMP assay, producing rightward shifts
in the concentration-effect curve of the CBR agonist CP-55,940. In conclusion, newer
classes of SERMs exhibit improved pharmacological characteristics (e.g., in CBR affinity
and selectivity) relative to initial studies with tamoxifen, and thus suggest that different
SERM scaffolds may be useful for development of safe and selective drugs acting via
CBRs.
Keywords: SERM, cannabinoid, CB1, CB2, inverse agonist, antagonist, G-protein coupled receptor, drug
development
Abbreviation:BAZ, bazedoxifene; CB1R, Cannabinoid Receptor Type 1; CB2R, Cannabinoid Receptor Type 2; ER, estrogen
receptor, NAF, nafoxidine, OSP, ospemifene; RAL, raloxifene; SERM, selective estrogen receptor modulator.
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INTRODUCTION
Selective estrogen receptor modulators act as agonists or
antagonists at estrogen receptors (ERs) in a tissue specific
fashion (Arnott et al., 2014). SERMs are used for several
therapeutic purposes including treating ER-positive breast
cancer, preventing osteoporosis, and mitigating postmenopausal
conditions including dysregulation of bone density and serum
lipids (Maximov et al., 2013). The first SERM that was successfully
used for its antiestrogenic activity to treat breast cancer was
tamoxifen. Although tamoxifen acts as an ER antagonist in breast
tissue, it exhibits agonist activity at ERs in the uterus, which
increases the risk and incidence of endometrial cancer (Maximov
et al., 2013). In addition to these undesired agonist effects in
the uterus, tamoxifen can produce other adverse side effects
including hot flashes, increased risk of stroke and pulmonary
embolism, and ocular changes (Arnott et al., 2014). In attempt
to develop drugs in this class with fewer risks and side effects
than tamoxifen, additional SERMs were synthesized that exhibit
different tissue-specific activity (Arnott et al., 2014). Compounds
developed based on tamoxifen as a scaffold are classified as
triphenylethylene SERMs. Other classes of SERMs exhibiting
varying degrees of affinity for ERα and ERβ with desirable tissue
specificity are grouped structurally into the benzothiophene,
tetrahydronaphthalene, indole, or benzopyran classes (Figure 1)
(Arnott et al., 2014).
FIGURE 1 | Representative compounds from five structurally distinct SERM classes examined in this study. Specific compounds studied were:
(A) tamoxifen, (B) ospemifene, (C) raloxifene, (D) nafoxidine, (E) bazedoxifene, and (F) acolbifene.
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Drugs in the five major classes of SERMs were originally
designed to treat hormone-sensitive forms of cancers, bone
disorders, and cardiovascular issues. However, many of these
SERMs at higher doses have surprisingly been shown to also
produce cytotoxicity in cancers devoid of the ERs (Nagahara
et al., 2013). Our laboratory and others (Kumar and Song,
2013; Prather et al., 2013) have suggested that cannabinoids
receptors (CBRs) might represent one potential ER-independent
mechanism responsible for SERM cytotoxicity in some forms of
cancer. For example, SERMs bind to the CBRs with moderate to
high affinity (Kumar and Song, 2013; Prather et al., 2013), and
SERMs and cannabinoids exhibit overlapping anti-proliferative,
anti-angiogenic and pro-apoptotic actions.
Cannabinoids receptors are seven trans-membrane
domain-spanning receptors that couple to the Gi/o-subtype
of G-proteins. There are two commonly accepted receptor
subtypes: cannabinoid type-1 (CB1) and cannabinoid type-2
(CB2) (Pisanti et al., 2013). CB1 receptors are expressed in
highest density in the central nervous system (CNS) but are also
present in other tissues, including reproductive organs and the
gastrointestinal tract (Cabral et al., 2015). CB2 receptors are also
present in low levels in the nervous system, but are expressed in
greatest abundance in, and modulate the function of, immune
cells (Cabral et al., 2015). Ligands that bind to and modulate
the activity of CBRs (e.g., cannabinoids) are structurally diverse
and range from compounds that are endogenously produced
(endocannabinoids), to plant-derived (phytocannabinoids)
and synthesized compounds (synthetic cannabinoids). In
addition to acting at CB1 and CB2 receptors, cannabinoids
have also been shown to produce effects via modulation of
other targets including peroxisome proliferator-activated
receptors (PPAR) (Martinez et al., 2015) and transient receptor
potential vanilloid type-1 (TRPV1) channels (Morgese et al.,
2007). The only cannabinoids that are currently approved by
the FDA for therapeutic purposes are plant-derived and act
non-selectively at CB1 and CB2Rs (Pertwee, 2010). Synthetic
cannabinoids, however, have been developed that act selectively
at CB1 or CB2 receptors. Ligands acting via CB1 receptors
primarily modulate CNS function and have been investigated
for potential therapeutic uses including neuroprotection during
epilepsy, Parkinson’s disease, Huntington’s disease, pain, nausea
and for appetite enhancement (Pertwee, 2010; García et al.,
2011; Valdeolivas et al., 2012). Development of CB2-selective
cannabinoids may also prove useful for treatment of immune-
related disorders by altering inflammation and cytokine levels
(Xu et al., 2007; Cabral and Griffin-Thomas, 2009), cancer
via anti-proliferative and anti-angiogenic effects (Vidinsky
et al., 2012), and chronic neuropathic pain (Wilkerson et al.,
2012).
Thus, development of cannabinoids with high affinity and
selectivity for either CB1 or CB2 receptors could allow for a
more targeted therapeutic approach for treatment of a variety
of disease states with reduced side effects. Tamoxifen has been
used safely for decades and binds non-selectively to CB1 and
CB2 receptors with affinity in the low µM range (Kumar and
Song, 2013; Prather et al., 2013). To identify cannabinoids with
improved pharmacological characteristics relative to tamoxifen,
and investigate the usefulness of SERM scaffolds for future
cannabinoid drug development, the purpose of this study was to
characterize the affinity and activity of SERMs in newer structural
classes at CBRs.
MATERIALS AND METHODS
Materials
All SERMs were obtained from the following commercial
sources. tamoxifen and Y-134 were purchased from Tocris
Bioscience (Bristol, United Kingdom). N-desmethyl tamoxifen,
4-hydroxy tamoxifen, endoxifen, SO4-tamoxifen, toremifene, 4-
hydroxy toremifene, OSP, RAL, lasofoxifene, NAF, and BAZ
were all obtained from Sigma Aldrich (St. Louis, MO, USA).
Acolbifene was procured from AdooQ Bioscience (Irvine, CA,
USA).
AM-630, AM-251, DAMGO, and WIN-55,212-2 were
purchased from Tocris Bioscience. CP-55,940 was obtained from
Santa Cruz Biotechnology, Inc. (Dallas, TX, USA). [35S]GTPγS
(1250 Ci/mmol) was procured from American Radiolabeled
Chemicals (St. Louis, MO, USA) and [3H]CP-55,940 (131.4
Ci/mmol) was purchased from PerkinElmer (Waltham, MA,
USA).
All other reagents were purchased from Fisher Scientific Inc.
(Pittsburgh, PA, USA). All compounds were dissolved in 100%
DMSO to produce a stock concentration of 10 mM.
Methods
Cell Culture
All experiments were conducted using intact cells or membranes
prepared from Chinese hamster ovary (CHO) cells stably
transfected with either human cannabinoid type-1 receptors
(CHO-hCB1), human cannabinoid type-2 receptors (CHO-
hCB2) (Shoemaker et al., 2005), or human mu opioid receptors
(CHO-hMOR) (Seely et al., 2012). CHO-hCB1 cells were
purchased from DiscoverRx Corporation (Fremont, CA, USA)
and cultured in HAM’s F-12 K media (ATCC, Manassas,
VA, USA). CHO-hCB2 and CHO-hMOR cells were cultured
in DMEM (Mediatech Inc., Manassas, VA, USA). All media
contained 10% Fetalplex, (Gemini Bioproducts, Sacramento,
CA, USA), 0.05 IU/mL penicillin, 50 µg/mL streptomycin
(Invitrogen, Carlsbad, CA, USA), and 250 µg/mL of Geneticin
(G418; Sigma-Aldrich, St. Louis, MO, USA). Cells were cultured
in a 37◦C humidified incubator with 5% CO2 and harvested with
PBS (10 mM)/EDTA (1 mM) when 80% confluent. All cells used
were maintained between passages 4–15.
Membrane Preparation
Membrane homogenates were prepared for competition receptor
binding and [35S]GTPγS binding studies by using pellets
previously frozen of CHO-hCB1 or CHO-hCB2 cells as described
in (Franks et al., 2014). In short, pellets were thawed on
ice, combined in a 40 ml glass Dounce homogenizer and
homogenized in 20 ml of cold buffer (50 mM HEPES at pH 7.4,
3 mM MgCl2, and 1 mM EGTA) using 10 strokes. Homogenates
were then centrifuged at 40,000 × g for 10 min at 4◦C.
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After discarding the supernatant, pellets were homogenized and
centrifuged twice more. Final pellets were re-suspended in ice-
cold 50 mM HEPES, pH 7.4, aliquoted and stored at −80◦C for
future use. Protein concentration was determined the same day,
prior to freezing, using BCATM Protein Assay (Thermo Fisher
Scientific, Waltham, MA, USA).
Competition Receptor Binding
Competition receptor binding was conducted by using 0.2 nM of
the radioligand [3H]CP-55,940, a high-affinity and non-selective
cannabinoid agonist as reported previously (Prather et al., 2013).
The final volume of each sample was 1 ml, containing 50 mM
Tris-HCl buffer (pH 7.4), 0.05% bovine serum albumin, 5 mM
MgCl2, increasing concentrations of non-radioactive competing
SERM ligands, and either 100 µg of CHO-hCB1 or 50 µg of
CHO-hCB2 membrane homogenates. Non-specific binding was
defined by radioactivity remaining in the presence of 1 µM
of the non-radioactive CB1/CB2 agonist WIN-55,212-2. Each
sample condition was performed in triplicate and allowed to
reach equilibrium at room temperature for 90 min. Reactions
were terminated by rapid vacuum filtration through Whatman
GF/B glass fiber filters (Brandel, Inc.), followed by four 4 ml
washes of ice-cold filtration buffer (50 mM Tris at pH 7.4
and 0.05% BSA). Filter punches of individual samples were
placed in scintillation vials containing 4 mls of ScintiverseTM
BD cocktail scintillation fluid (Fisher Scientific, Pittsburg, PA,
USA). Final counts were determined using liquid scintillation
spectrophotometry (Tri Carb 2100 TR Liquid Scintillation
Analyzer, Packard Instrument Company, Meriden, CT, USA)
after overnight incubation.
[35S]GTPγS Binding
The [35S]GTPγS binding assay was conducted as described
previously (Prather et al., 2013) in a final volume of 1 ml
by incubating 0.1 nM [35S]GTPγS in 20 mM HEPES with
10 mM MgCl2, 100 mM NaCl, 10 µM GDP, 0.1% bovine
serum albumin, varying concentrations of SERM ligands, and
either 25 µg of CHO-hCB2, 50 µg of CHO-hCB1 or 50 µg
of CHO-hMOR membranes homogenates. Non-specific binding
was defined by radioactivity remaining in the presence of 10 µM
of non-radioactive GTPγS. All reactions were incubated for
30 min at 30◦C, terminated by filtration through Whatman
GF/B glass fiber filters (Brandel, Inc.) and followed by four
4 ml washes of ice cold filtration buffer (50 mM HEPES, pH
7.4) containing 0.1% bovine serum albumin. Filter punches of
individual samples were placed in scintillation vials containing
4 mls of ScintiverseTM BD cocktail scintillation fluid (Fisher
Scientific, Pittsburg, PA, USA). Final counts were determined
using liquid scintillation spectrophotometry (Tri Carb 2100 TR
Liquid Scintillation Analyzer, Packard Instrument Company,
Meriden, CT, USA) after overnight incubation.
Adenylyl Cyclase Assay
Adenylyl cyclase activity was measured using intact CHO-
hCB1 or CHO-hCB2 cells, similar to that previously reported
(Rajasekaran et al., 2013). Briefly, cells cultured between passages
4 and 15 were seeded into 24-well plates at a concentration of 6.5
million cells per plate and incubated overnight in a humidified
incubator maintained at 37◦C and 5% CO2. Growth media was
removed the next day and replaced with media containing 2.5
Ci/ml [3H]adenine, 0.9g/L NaCl, and 0.5 mM isobutyl-methyl-
xanthine (IBMX) for 2–3 h. Radioactive media was then removed
and each well treated with 0.5 ml of varying concentrations of
SERM compounds in a Krebs-Ringer-HEPES solution (10 mM
HEPES, 110 mM NaCl, 25 mM Glucose, 55 mM Sucrose, 5 mM
KCl, 1 mM MgCl2, 1.8 mM CaCl2, pH 7.4 ) containing 0.5 mM
IBMX and 10 µM forskolin. Plates were then floated in a 37◦C
water bath for 15 min before reactions were terminated by
addition of 50 µL of 2.2 N HCl to each well.
For experiments to determine the ability of SERMs to
antagonize the inhibition of adenylyl cyclase activity by CP-
55,940, plates were seeded and incubated with [3H]adenine as
described above. After removal of radioactivity, SERMs were
preincubated with cells in Krebs-Ringer-HEPES solution for
30 min at room temperature prior to addition of increasing
concentrations of CP-55,940 (10−10-10−5M). Following
addition of CP-55,940, samples were further incubated at room
temperature for 7 min at room temperature. Reactions were
then terminated by adding 50 µL of 2.2 N HCl to each well.
[3H]cAMP was isolated using alumina column chromatography
and radioactivity quantified following addition of 10 mls of
scintiverseTM BD cocktail scintillation fluid (Fisher Scientific,
Pittsburg, PA, USA) by liquid scintillation spectrophotometry
(Tri Carb 2100 TR Liquid Scintillation Analyzer, Packard
Instrument Company, Meriden, CT, USA).
Statistical Analysis
Statistical analyses were conducted by utilizing GraphPad Prism
v6.0g (GraphPad Software, Inc.; San Diego, CA, USA). IC50
values from competition receptor binding curves were derived by
non-linear regression. Experimental IC50 values were converted
to Ki values (a measure of receptor affinity) by using the
Cheng–Prusoff equation (Cheng and Prusoff, 1973). Non-linear
regression analysis of concentration-effect curves was also used to
determine potency (ED50 or IC50) and efficacy (Emax or Imax) for
modulation of GTPγS and adenylyl cyclase activity, respectively.
All IC50, EC50, Ki, and Kb values were converted to pEC50,
pIC50, pKi, and pKb values in order to permit use of parametric
statistical analyses. For all experiments comparing three or more
values, an one-way ANOVA was employed, followed by Dunnett’s
or Tukey’s post hoc tests. For comparisons of two values, an
unpaired t-test was utilized. To determine significant radioligand
displacement or modulation of G-protein activity compared to
basal levels, a one-sample t-test was employed.
RESULTS
SERMs from Four of Five Structural
Classes Exhibit Affinity for CB1 and
CB2Rs
For initial comparison of potential SERM binding to CBRs, 14
commercially available compounds from 5 structurally distinct
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classes (Figure 1) were subjected to a radioligand binding
screen (Figure 2). Specifically, the ability of a single 1 µM
concentration of each SERM to displace 0.2 nM of the high
affinity, non-selective CB1R/CB2R radioligand [3H]CP-55,940
from human CB1 (CHO-hCB1) or CB2 (CHO-hCB2) receptors
stably expressed in CHO cells was examined. Based on these
experimental conditions, the Cheng–Prusoff equation (Cheng
and Prusoff, 1973) predicts that the concentration of a SERM
producing 50% displacement of [3H]CP-55,940 (e.g., IC50) from a
receptor will approximate the affinity (e.g., Ki) of that compound
for the receptor examined.
Selective estrogen receptor modulators in the
triphenylethylene class (1 µM) displace [3H]CP-55,940 from
both hCB1 and hCB2Rs by amounts ranging from little to
no displacement, to as high as 58% (Figure 2A). Specifically
for hCB1Rs (open bars), OSP, and the tamoxifen metabolites
4-hydroxy-tamoxifen (4OH-TX), endoxifen (ENDX), and
4-hydroxy-toremifene (4OH-TOR) produce the greatest
amount of [3H]CP-55,940 displacement of approximately 50%.
Concerning CB2Rs (filled bars), the triphenylethylenes produce
levels of [3H]CP-55,940 displacement similar to that from
hCB1Rs, from 5 to 58%. Importantly, data from this initial
binding screen predict that while 4OH-TX and 4OH-TOR
bind to hCB1 and hCB2Rs non-selectively (e.g., producing
similar levels of radioligand displacement at 1 µM from both
receptors), OSP exhibits some degree of selective affinity for
hCB1Rs.
Based on data from the initial screen, both compounds
in the benzothiophene group (Figure 2B) would be predicted
to bind to both CBRs with moderate to high affinity in the
nM range, with RAL producing 67 and 80% displacement of
[3H]CP-55,940 from hCB1 and hCB2Rs, respectively. SERMs in
the tetrahydronaphthalene class, lasofoxifene (LAS) and NAF,
also apparently exhibit appreciable affinity for CBRs, with LAS
predicted to bind relatively selectively to hCB2Rs. BAZ, the only
SERM commercially available from the indole group, appears to
exhibit higher affinity for the CB2 receptors, producing 29 and
73% displacement of [3H]CP-55,940 from hCB1 and hCB2Rs,
respectively. Finally, acolbifene, the sole compound available for
examination in the benzopyran group, fails to displace [3H]CP-
55,940 from either hCB1 or hCB2Rs and thus would be predicted
to have no affinity for CBRs.
FIGURE 2 | Selective estrogen receptor modulators from four of five structural classes exhibit affinity for CB1 and CB2Rs. Commercially available
compounds from 5 structurally distinct classes were subjected to a radioligand binding screen (A,B). The ability of a single 1 µM concentration of each SERM to
displace 0.2 nM of the high affinity, non-selective CB1R/CB2R radioligand [3H]CP-55,940 from hCB1 [open bars] or hCB2 [filled bars] receptors stably expressed in
CHO cells was examined. ∗,∗∗ Histograms that are designated by asterisks, are significantly different from 100% specific [3H]CP-55,940 binding (P < 0.05, 0.01;
One-sample t-test). a,b[3H]CP-55,940 binding of individual SERMs to hCB1 and hCB2 receptors designated by different letters, are significantly different (P < 0.05;
Student’s t-test).
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SERMs Act as Inverse agonists at CBRs
to Modulate G-Protein Activity
Selective estrogen receptor modulators that were predicted to
exhibit appreciable affinity for CBRs based on initial binding
studies were next screened for intrinsic activity (e.g., to determine
if these SERMs act as agonists, antagonists or inverse agonists at
CBRs; Figure 3). CBRs are coupled to Gi/Go type G-proteins.
Therefore, binding of agonists to CBRs leads to G-protein
activation, antagonists produce no effect, and inverse agonists
reduce basal G-protein activity produced by constitutively
active receptors. SERMs were screened by examining the
ability of a single receptor saturating concentration (10 µM)
FIGURE 3 | Selective estrogen receptor modulators act as inverse agonists at CBRs to modulate G-protein activity. SERMs predicted by initial binding
studies to exhibit appreciable affinity for CBRs, were next screened for intrinsic activity at (A) hCB1Rs, (B) hCB2Rs or (C) hMORs by examining [35S]GTPγS binding
in the presence or absence of a receptor-saturating concentration (10 µM) of all compounds. G-protein modulation by full agonists CP-55,940 (10 µM) and DAMGO
(10 µM) was examined to serve as positive controls for activation of (A,B) CBRs and (C) MORs, respectively. G-protein modulation by the inverse agonists AM-251
and AM-630 was examined to serve as positive controls for regulation of (A) CB1 and (B) CB2R signaling, respectively. The mean ± SEM of [35S]GTPγS binding is
presented as percent of basal G-protein activity in the presence of vehicle. ∗,∗∗ Histograms that are designated by asterisks, are significantly different from basal
activity (P < 0.05, 0.01; One-sample t-test). a[35S]GTPγS binding produced by individual SERMs acting at hCB1 or hCB2 receptors are significantly different that
binding produced by the CBR inverse agonists AM-251 (for hCB1Rs) or AM-630 (for hCB2Rs), respectively (P < 0.05; Student’s t-test).
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to modulate G-protein activity in membranes prepared from
CHO-hCB1 and CHO-hCB2 cells. G-protein activation was
quantified using employing [35S]GTPγS, a non-hydrolyzable
analog of GTP, that irreversibly binds to the G-proteins when
activated.
When examining intrinsic activity at hCB1Rs (Figure 3A),
as anticipated, the full hCB1/hCB2R agonist CP-55,940 (1 µM)
produces a 70% increase in [35S]GTPγS binding above basal
levels and the well-characterized CB1 inverse agonist AM-
251 (10 µM) reduces basal G-protein activity over 30%. All
SERMs examined, except 4OH-TX, RAL and Y-134, reduce basal
G-protein activity to levels similar to that produced by the full
inverse agonist AM-251. Therefore, 4OH-TX, RAL and Y-134
would be predicted to act as partial, while all other SERMs
examined act as full inverse agonists at CB1Rs.
Concerning G-protein modulation by SERMs at hCB2Rs
(Figure 3B), the full hCB1/CB2R agonist CP-55,940 (1 µM)
activates G-proteins by 17%, while the full hCB2R inverse
agonist AM-630 (10 µM) reduces G-protein activity by 34%.
Similar to intrinsic activity observed at hCB1Rs, all SERMs
from the four classes examined act as full inverse agonists,
with only Y-134 and LAS exhibiting partial inverse agonist
activity.
To demonstrate that the observed modulation of G-protein
activity by SERMs in transfected CHO cells occurs due to action
at CBRs, [35S]GTPγS binding assays were also conducted in
membranes prepared from CHO cells devoid of cannabinoid
receptors, but stably expressing mu-opioid receptors as a positive
control (CHO-hMOR) (Figure 3C). As anticipated, the full
mu-opioid agonist DAMGO increases G-protein activity by
53%. In marked contrast to that observed in CHO-hCB1 and
CHO-hCB2 membranes, in CHO-hMOR membranes all SERMs
except OSP do not alter basal G-protein activity. Although
OSP does decrease G-protein activity by 11% in CHO cells not
expressing CBRs, this SERM reduces basal G-protein activity to
a much greater level (e.g., ∼30%) in CHO cells expressing CBRs.
Taken collectively, these data strongly indicate that reduction in
G-protein activity produced by all SERMs screened in CHO-
hCB1 and CHO-hCB2 cells occurs specifically due to interaction
with CBRs.
SERMs Bind With High Affinity (e.g., Ki
Values) and Differential Selectivity to
CB1 and CB2Rs
To more fully characterize SERMs from different structural
classes, one compound from each class was selected based on
distinctive characteristics identified by the initial binding screen.
For example, the triphenylethylene OSP and the indole BAZ
were selected due to potential selective affinity for hCB1 and
hCB2Rs, respectively. Although the benzothiophene RAL and
tetrahydronaphthalene NAF appear to bind non-selectively to
hCB1 and hCB2Rs, both were selected for further analysis due
to predicted high affinity for CBRs based on the binding screen.
The benzopyran acolbifene was not selected for further studies
because 1 µM of this SERM did not produce any displacement of
[3H]CP-55,940 from either CBR.
The affinity (Ki) of each compound was determined by full
competition receptor binding curves (Figure 4) employing the
CB1/CB2R radioligand [3H]CP-55,940 in membranes prepared
from CHO-hCB1 and CHO-hCB2 cells. Ki values were derived
from experimental IC50 values employing the Cheng–Prusoff
equation (Cheng and Prusoff, 1973) and are presented in Table 1.
For hCB1Rs, RAL exhibits the highest affinity with a Ki value of
210 nM, while NAF, OSP and BAZ bind to hCB1Rs with moderate
affinity in the sub-micromolar range. Considering CB2Rs, RAL
and BAZ exhibit high affinity with Ki values in the low nM
range (240 and 254 nM, respectively). NAF and OSP bind to
hCB2Rs with statistically lower affinity (1–4 µM) than RAL
or BAZ. As predicted by the initial binding screen (Figure 2),
OSP binds relatively selectively to hCB1Rs with a CB1/CB2
ratio of 0.20, while BAZ exhibits selectivity for hCB2Rs with a
CB1/CB2 ratio of 3.29. Also as predicted, RAL and NAF lacked
any selectivity and bound to both hCB1and hCB2Rs with similar
affinity.
Collectively, these data suggest that the different SERM
scaffolds can be modified to develop non-selective and selective
hCB1 and hCB2R ligands with high affinity.
SERMs Modulate G-Protein Activity With
Potencies Predicted by Affinity for hCB1
and hCB2Rs
To further characterize intrinsic activity at CBRs, full
concentration-effect curves were conducted to determine
the potency (IC50) and efficacy (Imax) for SERM modulation of
G-protein activity by hCB1 and hCB2Rs (Figure 5; Table 2).
Concerning hCB1Rs (Figure 5A), OSP and RAL potently
reduce basal G-protein activity with IC50 values of 170 and
143 nM. Both SERMs are significantly more potent than
either NAF or BAZ. Importantly, the rank order of potency
for CB1R-mediated G-protein modulation by these SERMs
is identical to the rank order of their affinity for CB1Rs
(e.g., RAL > OSP > NAF = BAZ). When considering
efficacy, as predicted by the initial intrinsic efficacy screen
(Figure 3), all SERMs except RAL acted as full inverse agonists at
hCB1Rs.
When examining activity at hCB2Rs (Figure 5B), BAZ and
RAL more potently (IC50 = 71.6 and 87.1 nM, respectively)
reduce basal G-protein activity when compared to OSP or
NAF. As observed for hCB1Rs, the rank order of potency
for CB2R-mediated G-protein modulation by these SERMs is
identical to the rank order of their affinity for CB2Rs (e.g.,
RAL = BAZ > NAF > OSP). All SERMs were relatively equally
efficacious, maximally reducing G-protein activity via hCB2Rs
with Imax values of approximately 40%.
SERMs Also Act as Inverse CB2 Agonists
to Modulate of Adenylyl Cyclase Activity
To provide a second measure of intrinsic activity, the ability of
SERMs to modulate intracellular levels of cAMP in intact cells
was examined (Figure 6). CBRs couple to Gi/Go-proteins, and
thus cannabinoid agonists inhibit activity of the downstream
intracellular effector adenylyl cyclase, reducing intracellular
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FIGURE 4 | Selective estrogen receptor modulators bind with high affinity and differential selectivity to CB1 and CB2Rs. A measure of affinity (Ki) of
(A) OSP, (B) RAL, (C) NAF, and (D) BAZ for CB1 and CB2Rs was obtained by conducting competition binding studies, employing 0.2 nM [3H]-CP-55,940 and
increasing concentrations of SERMs (10−10 to 10−5M). Ki values (mean ± SEM) were derived from non-linear regression analysis of the curves shown by using the
Cheng–Prusoff equation (Cheng and Prusoff, 1973). Individual Ki values and statistical analysis of pKi values are presented in Table 1. Filled symbols represent
binding of SERMs to CB2Rs, open symbols represent binding of SERMs to CB2Rs.
TABLE 1 | Competition binding between ospemifene, raloxifene, nafoxidine, and bazedoxifene and the CBR agonist [3H]CP-55,940 employing CHO-hCB1
and CHO-hCB2 membranes.
Drug [3H]CP-55,940 Binding
CHO-hCB1 CHO-hCB2 Selectivity
Ki (nM) pKi N Ki (nM) pKi N (CB1/CB2)
OSP 753 6.123 ± 0.060a 5 3715 5.430 ± 0.033a,∗∗ 3 0.20
RAL 210 6.677 ± 0.063b 4 240 6.620 ± 0.037b 3 0.88
NAF 957 6.019 ± 0.084a 3 1300 5.886 ± 0.044c 3 0.74
BAZ 836 6.078 ± 0.066a 5 254 6.595 ± 0.023b,∗∗ 5 3.29
a,b,cpKi values designated by different letters are significantly different from values in the same column; P < 0.05, one-way ANOVA, Tukey Post-hoc test. ∗∗ pKi values for
individual SERMs examined at hCB2 receptors are significantly different from pKi values for same compounds at hCB1 receptors; P < 0.01, student’s t-test.
cAMP levels. Cannabinoid antagonists do not affect cAMP levels,
and inverse agonists increase cAMP levels due to inhibition of
constitutively active CBRs.
Modulation of adenylyl cyclase activity by hCB1Rs could not
be examined in CHO-hCB1 cells because all SERMs tested, as
well as the well established hCB1R full inverse agonist AM-251
(with concentrations as high as 10 µM) do not alter basal cAMP
levels (data not shown). This indicates that the CHO-hCB1 cell
line likely does not express a sufficient density of constitutively
active CB1Rs to detect inverse agonism in this assay.
However, as predicted by intrinsic activity observed for
hCB2R modulation of G-protein activity (Figure 5B), all SERMs
examined similarly act as inverse agonists at CB2Rs, producing
robust increases intracellular cAMP levels (Figure 6A; Table 3).
BAZ, OSP and RAL elevate cAMP with Emax values of 352,
279 and 234%, respectively. Very interestingly, all SERMs
examined are more efficacious when compared to the well-
established full inverse agonist AM-630, which increases cAMP
levels in CHO-hCB2 cells by only 214 ± 6.4% (Table 3).
When considering potency, RAL increases cAMP levels most
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FIGURE 5 | Selective estrogen receptor modulators modulate
G-protein activity with potencies predicted by affinity for hCB1 and
hCB2Rs. The ability of OSP (circles), RAL (upward triangles), NAF (downward
triangles) and BAZ (squares) to modulate G-protein activity via (A) CB1Rs and
(B) CB2Rs was evaluated by examining [35S]GTPγS binding in the presence
increasing concentrations (10−10 to 10−5M) of all SERMs. All IC50 and IMAX
values (mean ± SEM) were derived from non-linear regression analysis of the
curves shown and are presented in Table 2 with statistical analysis.
potently with an EC50 of 873 nM, while the potency of
OSP and BAZ is only in the low micromolar range. As
anticipated, based on lower affinity for hCB2Rs, all SERMs
were also less potent than AM-630 in this assay. Quantification
of the intrinsic activity of NAF for regulation of adenylyl
cyclase activity in CHO-hCB2 cells could not be determined
due to solubility limitations that precluded examination of
concentrations high enough for calculation of accurate EC50
and Emax values. Modulation of adenylyl cyclase activity in
CHO-hCB2 cells by SERMs is mediated by hCB2Rs because
basal cAMP levels in CHO-hMOR cells, that do not express
hCB2Rs, are only slightly altered by one SERM (e.g., BAZ)
(Figure 6B).
SERMs Produce Surmountable
Antagonism of CP-55,940 Inhibition of
Adenylyl Cyclase in CHO-hCB1 Cells
To demonstrate potential pharmacological relevance and
provide additional support that SERMs act as CBR inverse
agonists/antagonists, antagonist dissociation constants (e.g., Kb
values) were determined by examining the effect of SERM co-
incubation on the potency (IC50) and efficacy (Imax) of CP-55,940
modulation of adenylyl cyclase activity in intact CHO-hCB1
and CHO-hCB2 cells (Figures 7 and 8). IC50 and Kb values
were converted to pIC50 and pKb values (pIC50 = -Log[IC50]
or pKb = -Log[Kb], respectively) to allow use of parametric
statistics for comparison.
In absence of co-incubation with any SERM, the CB1/CB2R
full agonist CP-55,940 produces a concentration-dependent
decrease in cAMP production with a potency (IC50) of 10.4 nM
and an efficacy (Imax) of 36.0% in intact CHO-hCB1 cells
(Figure 7; Table 4). To obtain a near maximal response, a
receptor saturating concentration of each SERM (based on
receptor affinity) was selected for co-incubation with CP-
55,940. Co-incubation with all SERMs produces a significant
decrease in potency, but not efficacy, of CP-55,940-mediated
inhibition of adenylyl cyclase activity (Table 4). Graphically, this
is observed as a parallel rightward shift in the concentration-
effect curve for CP-55,940 (Figures 7A–D), and indicates that
all SERMs act as surmountable CB1R antagonists in this assay.
The degree of shift produced by co-incubation was used to
calculate a Kb value for each SERM (the antagonist dissociation
constant), a quantifiable measure of antagonism. The high
affinity and well characterized CB1R inverse agonist/antagonist
AM-281, produces a 16-fold decrease in potency of CP-55,940
TABLE 2 | Modulation of GTPγS binding by SERMs employing CHO-hCB1 and CHO-hCB2 membranes.
Drug GTPγS Binding (% Basal)
CHO-hCB1 CHO-hCB2
IC50 (nM) pIC50 IMAX (%) N IC50 (nM) pIC50 IMAX (%) N
OSP 170 6.769 ± 0.147a 30.3 ± 2.0a 3 558 6.253 ± 0.117a,∗∗ 39.7 ± 2.4a,∗∗ 3
RAL 143 6.846 ± 0.174a 11.7 ± 4.7b 3 87.1 7.060 ± 0.190b 34.3 ± 2.2b,∗∗ 3
NAF 524 6.281 ± 0.105b 31.7 ± 1.5a 3 344 6.463 ± 0.073a 38.7 ± 1.2a,b,∗∗ 3
BAZ 1164 5.934 ± 0.146b 29.7 ± 1.9a 3 71.6 7.145 ± 0.085b,∗∗ 34.0 ± 1.0b,∗ 3
a,bpIC50 or IMAX values designated by different letters are significantly different from values in the same column; P < 0.05, one-way ANOVA, Tukey Post hoc test. ∗,∗∗pIC50
or IMAX values for individual SERMs examined at hCB2 receptors are significantly different from pIC50 or IMAX values for same compounds at hCB1 receptors; P < 0.05,
0.01, student’s t-test.
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FIGURE 6 | Selective estrogen receptor modulators also act as inverse
CB2 agonists to modulate of adenylyl cyclase activity. The potency
(EC50) and efficacy (EMAX) for modulation of forskolin-stimulated adenylyl
cyclase activity was evaluated by analyzing concentration-effect curves (10−8
to 10−5M) for OSP (circles), RAL (triangles) and BAZ (squares) in intact
CHO-hCB2 cells (A). All IC50 and IMAX values (mean ± SEM) were derived
from non-linear regression analysis of the curves shown and are presented in
Table 3 with statistical analysis. In (B), CHO-hMOR cells were employed as a
positive control, and adenylyl cyclase activity was measured in the presence
of a receptor saturating concentration (10 µM) of the mu-opioid agonist
DAMGO, or the SERMs OSP, RAL, NAF, and BAZ. The mean ± SEM of cAMP
production is presented as percent of basal adenylyl cyclase activity in the
presence of vehicle. ∗∗Bar graphs in (B) that are designated by asterisks, are
significantly different from basal activity (P < 0.01; One-sample t-test).
with a calculated a Kb value of 155 nM (Table 4). Although
all SERMs clearly act as surmountable hCB1R antagonists,
the rank order of Kb values for SERM antagonism of CP-
55,940 inhibition of adenylyl cyclase activity via hCB1Rs (e.g.,
OSP > RAL = NAF > >BAZ; Table 4) fails to completely
correlate with the rank order of affinity of these compounds
for hCB1Rs (e.g., RAL > OSP = NAF = BAZ; Table 1). For
example, because RAL exhibits highest affinity (e.g., lowest Ki
value) for hCB1Rs, this SERM would also be predicted to act
as the antagonist with the lowest Kb value. However, this was
not observed, with OSP instead exhibiting the lowest Kb value
of 210 nM (Table 4), while displaying only moderate affinity for
CB1Rs of 753 nM (Table 1).
TABLE 3 | Modulation of adenylyl cyclase activity by SERMs in intact
CHO-hCB2 cells.
Drug Intracellular [3H]cAMP
EC50 (nM) pEC50 EMAX (%) N
OSP 1445 5.840 ± 0.096a,b 279 ± 17.0a 3
RAL 873 6.059 ± 0.088a 234 ± 21.0b 3
BAZ 1982 5.703 ± 0.105b 352 ± 14.0c 3
AM-630† 398 6.40 ± 0.096c 214 ± 6.5b 4
a,b,cpEC50 and EMAX values designated by different letters are significantly different
from values in the same column; P < 0.05, one-way ANOVA, Tukey Post-hoc test.
†Values obtained from Ford et al. (2016).
SERMs Produce Surmountable and
Insurmountable Antagonism of
CP-55,940 Inhibition of Adenylyl Cyclase
Activity in CHO-hCB2 Cells
The same co-incubation strategy was applied to determine
Kb values for SERMs acting via hCB2Rs (Figure 8; Table 5).
When incubated alone with intact CHO-hCB2 cells, the
full CB1/CB2R agonist CP-55,940 inhibited adenylyl cyclase
activity in a concentration-dependent manner with a potency
(IC50) of 8.62 nM and an efficacy of (Imax) of 36.1%.
As anticipated, co-incubation with the established hCB2R
inverse agonist/antagonist AM-630 resulted in a 33-fold parallel
shift-to-the-right in the concentration-effect curve of CP-
55,940, resulting in a calculated Kb value of 55.4 nM
(Table 5).
As observed with hCB1Rs, SERM co-incubation in CHO-
hCB2 cells also results in significant decreases in the potency
(e.g., higher IC50 values) of CP-55,940 to inhibit adenylyl
cyclase activity (Table 5), as reflected by shifts to the right in
all concentration-effect curves (Figure 8). Three of the four
SERMs examined (RAL, NAF and OSP) also do not alter
the efficacy (e.g., Imax value) of CP-55,940, indicating that
these compounds likely act as surmountable antagonists at
hCB2Rs. Furthermore, unlike that observed for hCB1Rs, the
rank order of Kb values for SERM-antagonism of adenylyl
cyclase activity by CP-55,940 via hCB2Rs, correlates well with
the rank order of affinity of these compounds for hCB2Rs (e.g.,
RAL > NAF > OSP; Table 1). Interestingly, co-incubation
with BAZ (a SERM in the indole structural class), significantly
decreases the efficacy (Imax) of CP-55,940 in this assay, suggesting
this compound appears to act as an insurmountable antagonist
at hCB2Rs. The Kb value for BAZ acting via hCB2Rs could
not be determined because insurmountable antagonism violates
the assumption of competitive antagonism required for Kb
calculation.
DISCUSSION
The major findings of this study are that compounds within
four of five structurally distinct classes of SERMs bind to
CBRs with moderate to high affinity, exhibit differential CB1
and CB2 selectivity, and act as partial or full inverse agonists.
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TABLE 4 | Selective estrogen receptor modulator antagonism of CP-55,940 inhibition of adenylyl cyclase activity in intact CHO-hCB1 cells.
Drug Intracellular [3H]cAMP
Pre-Incubation IC50 (nM) pIC50 IMAX (%) Kb (nM) pKb N
CP-55,940 —— 10.4 7.982 ± 0.125 36.0 ± 2.2 —— —— 4
+OSP 10 µM 614 6.212 ± 0.078∗∗ 43.8 ± 2.7 173 6.762 ± 0.122a 4
+RAL 2 µM 26.6 7.575 ± 0.200∗ 38.7 ± 1.9 1122 5.950 ± 0.062b 3
+NAF 10 µM 102 6.990 ± 0.118∗∗ 38.3 ± 1.7 1164 5.934 ± 0.161b 4
+BAZ 10 µM 30.5 7.515 ± 0.176∗∗ 35.3 ± 0.7 4519 5.345 ± 0.044c 3
+AM-281† 1 µM 166 6.78 ± 0.053∗∗ 35.7 ± 0.9 155 6.810 ± 0.061a 3
∗,∗∗pIC50 and IMAX values are significantly different from the pIC50 and IMAX value for CP-55,940; P < 0.05, 0.01, one-way ANOVA, Dunnett’s Post hoc test. a,b,cpKb
values designated by different letters are significantly different from values in the same column; P < 0.05, one-way ANOVA, Tukey Post hoc test. †Values obtained from
Ford et al. (2016).
Although two initial reports have shown that a limited number
SERMs bind to CB2Rs (Kumar and Song, 2013, 2014; Prather
et al., 2013), no studies other than our initial observations
with tamoxifen (Prather et al., 2013) have investigated whether
these compounds also exhibit potential affinity and activity at
CB1Rs, or if additional SERMs might exhibit higher affinity
and/or selectivity for binding to CB1 or CB2Rs. Observations
reported here demonstrate that newer classes of SERMs exhibit
FIGURE 7 | Selective estrogen receptor modulators produce surmountable antagonism of CP-55,940 inhibition of adenylyl cyclase in CHO-hCB1
cells. CHO-hCB1 cells were pre-incubated for 30 min with receptor saturating concentrations of individual SERMs and were subsequently co-incubated for 7 min
with increasing concentrations of CP-55,940. Measurements of CP-55,940 effects alone on potency (IC50) and efficacy (IMAX) of intracellular cAMP were obtained
and were compared to the shifts in IC50 and IMAX values observed by co-incubation with individual SERMS: (A) Ospemifene, (B) Raloxifene, (C) Nafoxidine, and (D)
Bazedoxifene. All IC50, IMAX and Kb values (mean ± SEM) were derived from non-linear regression analysis of the curves shown and are presented in Table 4 with
statistical analysis. Asterisk symbols represent the concentration-effect curve for CP-55,940 alone, while open symbols the action of CP-55,940 in the presence of
the SERM indicated.
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FIGURE 8 | Selective estrogen receptor modulators produce surmountable and insurmountable antagonism of CP-55,940 inhibition of adenylyl
cyclase activity in CHO-hCB2 cells. CHO-hCB2 cells were pre-incubated for 30 min with receptor saturating concentrations of individual SERMs and were
subsequently co-incubated for 7 min with increasing concentrations of CP-55,940. Measurements of CP-55,940 effects alone on potency (IC50) and efficacy (IMAX)
of intracellular cAMP were obtained and were compared to the shifts in IC50 and IMAX values observed by co-incubation with individual SERMS: (A) Ospemifene, (B)
Raloxifene, (C) Nafoxidine, and (D) Bazedoxifene. All IC50, IMAX, and Kb values (mean ± SEM) were derived from non-linear regression analysis of the curves shown
and are presented in Table 5 with statistical analysis. Asterisk symbols represent the concentration-effect curve for CP-55,940 alone, while filled symbols the action
of CP-55,940 in the presence of the SERM indicated.
TABLE 5 | Selective estrogen receptor modulator antagonism of CP-55,940 inhibition of adenylyl cyclase activity in inact CHO-hCB2 cells.
Drug Intracellular [3H]cAMP
Pre-Incubation IC50 (nM) pIC50 IMAX (%) Kb (nM) pKb N
CP-55,940 —— 8.62 8.246 ± 0.151 36.1 ± 2.83 —— —— 8
+OSP 10 µM 65.9 7.218 ± 0.124∗∗ 31.7 ± 2.3 1256 5.901 ± 0.222a 3
+RAL 2 µM 229 6.713 ± 0.100∗∗ 33.0 ± 1.3 66.5 7.177 ± 0.242b 6
+NAF 10 µM 226 6.691 ± 0.145∗∗ 32.3 ± 2.3 337 6.473 ± 0.187c 3
+BAZ 2 µM 52.9 7.309 ± 0.095∗∗ 28.8 ± 3.0∗∗ —— —— 4
+AM-630† 1 µM 288 6.540 ± 0.060∗∗ 31.7 ± 0.3 55.4 7.26 ± .064b 3
∗∗pIC50 and IMAX values are significantly different from the pIC50 and IMAX value for CP-55,940; P < 0.01, one-way ANOVA, Dunnett’s Post hoc test. a,b,cpKb values
designated by different letters are significantly different from values in the same column; P < 0.05, one-way ANOVA, Tukey Post hoc test. †Values obtained from Ford
et al. (2016).
improved pharmacological characteristics (e.g., in CBR affinity
and selectivity) relative to these initial studies, and thus suggest
that several of the distinct SERM scaffolds may be useful
for future development of safe and selective drugs acting via
CBRs.
Knowledge that SERMs act via CBRs at pharmacologically
relevant concentrations has potential therapeutic significance
for several reasons. First, although the most well established
mechanism of action for SERMs occurs through modulation
of ERs (Arnott et al., 2014; Ellis et al., 2015), interaction
with non-ER targets such as CBRs may expand therapeutic
actions of these compounds and explain currently observed
anti-cancer or anti-oxidant properties in tissues not expressing
ERs (Perry et al., 1995; Moreira et al., 2004; Arnott et al.,
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2014). For example, tamoxifen exhibits anti-tumor activity in
several types of cancer devoid of ERs, including pancreatic
(Tomao et al., 2002), glioma (Mastronardi et al., 1998) and
melanoma (Beguerie et al., 2010). Since both SERMs and
cannabinoids reduce tumor angiogenesis by inhibiting VEGF
(Blázquez et al., 2003; Garvin and Dabrosin, 2003), perhaps
this and other shared mechanisms of action might be due
to SERM interaction with CBRs. Second, in addition to
serving as potential ER-independent targets, CB2R expression
is significantly increased in several forms of ER positive breast
cancer, and is negatively correlated to patient survival (Pérez-
Gómez et al., 2015). Therefore, it is possible that SERMs
exhibiting a dual mechanism of action to both antagonize
ER function and act as CBR inverse agonists might exhibit
superior therapy and lead to development of a novel class of
specialized SERMs for use in personalized cancer therapy. Third,
in addition to treatment of osteoporosis and prevention of
breast cancer in post-menopausal women (Gizzo et al., 2013),
RAL has been shown to produce neuroprotective (Ishihara
et al., 2015) and beneficial cardiometabolic effects (Dayspring
et al., 2006), as well as improve cognition in both male and
female schizophrenic patients (Kindler et al., 2015). Although
involvement of ERs has been implicated for mediation of several
of these effects (Khan, 2016), CB1 antagonists/inverse agonists
similarly improve neurocognitive symptoms in schizophrenics
(Roser et al., 2010), are neuroprotective (Sommer et al.,
2006) and improve cardiometabolic measures (Ginsberg and
Woods, 2009). It is therefore tempting to speculate that
dual action of RAL at ERs and CBRs may contribute to
these potentially important therapeutic effects, and suggest a
need for further investigation and development of drugs with
similar mechanisms of action. Finally, given that cannabinoid
actions can also be mediated by receptors other than CB1
and CB2 (Morgese et al., 2007; Martinez et al., 2015), future
studies examining the affinity of SERMs for such additional
targets including PPAR and/or TRPV1 channels might be
informative.
Although dual action of SERMs at ERs and CBRs might
be therapeutically beneficial in some situations, it is possible
that interaction CBRs might also contribute to some of the
adverse effects observed with this class of compounds. For
example, tamoxifen use in humans (Yang et al., 2013) and
research of CBR inverse agonists demonstrate that both groups
of compounds increase bone mineralization, sensitivity to
nociception and may result in depression (Idris and Ralston,
2010; Buggy et al., 2011; Nazarali and Narod, 2014; Azizi-
Malekabadi et al., 2015). Furthermore, endogenously produced
cannabinoids (e.g., endocannabinoids) are important modulators
of cerebral blood flow (Benyo et al., 2016) and agonist
activation of CB2Rs reduces infarct volume and improves
functional outcome in experimental stroke (England et al., 2015).
Antagonism of CB2R function by SERMs might thus contribute
to the increased stroke incidence sometimes observed with this
class of drugs (Rizzoli et al., 2011). In any case, additional
research will be required to clearly delineate the participation
of CBRs in both potential therapeutic and adverse effects of
SERMs.
Another, and perhaps most important, implication from
findings presented here is the potential for development of a
novel class of drugs based on different SERM scaffolds that
act selectively via CBRs. As an initial step toward development
of CBR selective SERM-based drugs, new compounds must be
designed to lack affinity for ERs. Interestingly, such studies
to reduce ER affinity while maintaining anti-cancer activity of
SERMs in the triphenylethylene class, as a means to discover
novel anti-cancer targets, are already underway (Guo et al.,
2013b). For example, several tamoxifen analogs, designated as
the ridaifen compounds, retain growth inhibition in multiple
cancer cell lines similar to that of tamoxifen, while totally
lacking affinity for ERs (Guo et al., 2013a,b). One ridaifen
compound in particular (ridaifen-B) induces autophagy in a
human T-cell lymphoma cell line devoid of estrogen receptors
(Nagahara et al., 2013), implicating a novel non-ER target
for this class of compounds. Importantly, ridaifen compounds
exhibit growth-inhibitory effects in many types of cancer that
are similarly sensitive to cannabinoids, such as ER-negative
breast cancer, gliomas, lung carcinoma, prostate cancer and
leukemia/lymphoma (McKallip et al., 2006; Chakravarti et al.,
2014; Nabissi et al., 2015). Cannabinoids produce efficacious
anti-tumor activity by a variety of mechanisms, including
inhibition of proliferation, induction of apoptosis, and inhibition
of angiogenesis (Chakravarti et al., 2014). Collectively, these
studies suggest that high affinity selective cannabinoids based
on the triphenylethylene SERM scaffold, lacking ER affinity,
might represent a novel class of drugs used to treat cancer
that act via an ER-independent mechanism of action. In
addition to anti-cancer activity, pre-clinical and clinical studies
of CB1R inverse agonists have shown that drugs with this
mechanism of action reduce appetite, body weight, insulin
resistance, and hepatic steatosis, while CB2R inverse agonists
act as potent and efficacious anti-inflammatory agents in a
variety of disease states (Tam et al., 2012; Presley et al., 2015).
Therefore, development of novel SERM-based selective CBR
inverse agonists, lacking ER affinity, may exhibit improved
safety relative to currently available compounds acting via
CBRs.
Despite the limited number of compounds available for
examination in the present study for each structural class,
some potential structural activity relationships may be worth
noting. All groups have a degree of structural likeness, consisting
of three planar benzyl rings providing similarity to estrogen
(Maximov et al., 2010) (Figure 1). Compounds in each class
also contain a chemical moiety unique to each structural
class that may participate in binding to CBRs, providing
enhanced affinity, selectivity and/or activity. For example, all
compounds in the triphenylethylene class contain a polar
R-group stemming from a phenol and exhibit only moderate
affinity for CBRs. However, SERMs in the benzothiophene, indole
and tetrahydronaphthalene class possess chemical moieties
present in recent designer synthetic cannabinoids (Debruyne and
Le Boisselier, 2015; Thaxton et al., 2015), and exhibit moderate to
high affinity for CBRs. The chemically distinct second generation
SERM RAL, containing a polyhydroxy phenol benzothiopene
group, exhibits highest, but similar affinity (∼200 nM) for both
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hCB1 and hCB2Rs. In contrast, altering the ER core binding
domain by introduction of a 2-phenyl-3-methyl indole contained
in the third generation SERM BAZ maintains high affinity for
hCB2Rs, while significantly decreasing hCB1R affinity. Finally,
removal of the 2-dimethylamino-ethoxy moiety of tamoxifen
to produce OSP, apparently increases affinity for CB1, but not
CB2Rs. Although current information concerning structural
activity relationships for SERM interaction with CBRs is limited,
observations from this and future studies may form the basis for
design of more comprehensive medicinal chemistry studies to
systematically optimize affinity and potency of SERMs acting at
CB1 and/or CB2Rs.
In summary, this study characterized the affinity and activity
of SERMs in newer structural classes at CBRs to identify
cannabinoids with improved pharmacological properties relative
to initial studies with tamoxifen. It was found that newer
classes of SERMs bind to CBRs with higher affinity and exhibit
differential selectivity than tamoxifen, while exhibiting similar
inverse agonist activity. Therefore, different SERM scaffolds may
be useful for development of selective and non-selective drugs
acting via CBRs for treatment of cancer and a variety of other
disease states.
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